Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-22T16:50:00.456Z Has data issue: false hasContentIssue false
  • English
  • Français

Serum Anticonvulsant Concentrations in Epileptic Patients with Mental Symptoms

A Preliminary Report

Published online by Cambridge University Press:  29 January 2018

E. H. Reynolds  and
R. D. Travers
E. H. Reynolds
Affiliation:
Dept. of Neurology, Yale University Medical School, New Haven, Connecticut
R. D. Travers
Affiliation:
Yale University Medical School, New Haven, Connecticut 06510, U.S.A.
Get access Rights & Permissions [Opens in a new window]

Extract

The introduction of techniques for the measurement of the serum concentrations of anticonvulsant drugs has opened up new opportunities of studying epilepsy in many of its aspects. Until the present time authors have studied variations in, and factors effecting, the metabolism of the drugs, and the relationship of serum drug concentrations to seizure control and well known side effects (see Woodbury, Penry and Schmidt, 1972). In this paper we report some preliminary observations on drug concentrations in patients with and without marked changes in their mental state.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 124 , Issue 582 , May 1974 , pp. 440 - 445
Copyright
Copyright © Royal College of Psychiatrists, 1974 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Buchthal, F., and Svensmark, O. (1971). ‘Serum concentrations of diphenylhydantoin (phenytoin) and phenobarbital and their relation to therapeutic and toxic effects.’ Psychiatria, Neurologia Pet Neurochirurgia, 74, 117–36.Google Scholar
Finkelman, I., and Arieff, A. J. (1949). ‘Untoward effects of phenytoin sodium in epilepsy.’ Journal of the American Medical Association, 118, 1209–12.Google Scholar
Frantzen, E., Hansen, J. M., Hansen, O. E., and Kristensen, M. (1967). ‘Phenytoin (Dilantin) intoxication.’ Acta Neurologica Scandinivica, 43, 440–46.Google ScholarPubMed
Glaser, G. H. (1972). ‘Diphenylhydantoin toxicity’, in Antiepileptic Drugs (ed. Woodbury, D. M., Penry, J. K., and Schmidt, R. P.). New York: Raven Press.Google Scholar
Guerrant, J., Anderson, W. M., Fischer, A., Weinstein, M. R., Jaros, R. M., and Deskins, A. (1962). Personality in Epilepsy. Springfield: Thomas.Google Scholar
Husby, J. (1963). ‘Delayed toxicity and serum concentrations of phenytoin.’ Danish Medical Bulletin, 10, 236–9.Google Scholar
Hutt, S. J., Jackson, P. M., Belsham, A., and Higgins, G. (1968). ‘Perceptual-motor behaviour in relation to blood phenobarbitone level: a preliminary report.’ Developmental Medicine and Child Neurology, 10, 626–32.CrossRefGoogle Scholar
Ideström, C. M., Schalling, D., Garlquist, U., and Sjöqvist, F. (1972). ‘Acute effects of diphenylhydantoin in relation to plasma levels. Behavioural and psychological studies.’ Psychological Medicine, 2, 111–20.Google Scholar
Kutt, H., Winters, W., Kokenge, R., and McDowell, F. (1964). ‘Diphenylhydantoin metabolism, blood levels and toxicity.’ Archives of Neurology, 11, 642–8.Google Scholar
Lascelles, P. T., Kocen, R. S., and Reynolds, E. H. (1970). ‘The distribution of plasma phenytoin levek in epileptic patients.’ Journal of Neurology, Neurosurgery and Psychiatry, 33, 501–5.Google Scholar
Lennox, W. G. (1942). ‘Brain injury, drugs and environment as causes of mental decay in epilepsy.’ American Journal of Psychiatry, 99, 174–80.CrossRefGoogle Scholar
Lennox, W. G., and Lennox, M. A. (1960). Epilepsy and Belated Disorders. Boston: Little, Brown and Co.Google Scholar
Logan, W. J., and Freeman, J. M. (1969). ‘Pseudodegenerative disease due to diphenylhydantoin intoxication.’ Archives of Neurology, 21, 631–7.Google Scholar
Patel, H., and Grichton, J. V. (1968). ‘The neurologic hazards of diphenylhydantoin in childhood.’ Journal of Pediatrics, 73, 676–84.CrossRefGoogle ScholarPubMed
Perlo, V. P., and Schwab, R. S. (1969). ‘Unrecognised Dilantin intoxication’, in Modern Neurology (ed. Lock, S.). Boston: Little, Brown and Co.Google Scholar
Reynolds, E. H. (1970). ‘Iatrogenic disorders in epilepsy’, in Modern Trends in Neurology, No. 5 (ed. Williams, , Denis, ). London: Buttenvorths.Google Scholar
Reynolds, E. H. (1972). ‘Diphenylhydantoin: Hematologic aspects of toxicity’, in Antiepileptic Drugs (ed. Woodbury, D. M., Penry, J. K., and Schmidt, R. P.). New York: Raven Press.Google Scholar
Reynolds, E. H., Mattson, R. H., and Gallagher, B. B. (1972). ‘Relationships between serum and cerebrospinal fluid anticonvulsant drug and folic acid concentrations in epileptic patients.’ Neurology, 22, 841–4.CrossRefGoogle ScholarPubMed
Rosen, J. A. (1968). ‘Dilantin dementia.’ Transactions of the American Neurological Association, 93, 273.Google Scholar
Slater, E., Beard, A. W., and Glithero, E. (1963). ‘The schizophrenia-like psychoses of epilepsy.’ British Journal of Psychiatry, 109, 95–150.CrossRefGoogle Scholar
Travers, R. D., Reynolds, E. H., and Gallagher, B. B. (1972). ‘Variations in response to anticonvulsants in a group of epileptic patients.’ Archives of Neurology, 27, 29–33.Google Scholar
Woodbury, D. M., Penry, J. K., and Schmidt, R. P., (eds.) (1972). Antiepileptic Drugs. New York: Raven Press.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.